Altre lingue Arbutus Biopharma Corporation

Azioni

ABUS

CA03879J1003

Biotecnologia

Tempo reale stimato Cboe BZX Altri mercati azionari 18:41:30 12/06/2025			Variaz. 5gg	Var. 1 gen.
3,520 ^USD	+0,57%		+2,50%	+6,57%

14/05	Arbutus Biopharma Corporation pubblica i risultati finanziari relativi al primo trimestre chiuso al 31 marzo 2025	CI
07/05	Arbutus Biopharma Corporation presenta i dati degli studi clinici sui suoi due prodotti contro l'HBV, Imdusiran e AB-101, al Congresso 2025 dell'Associazione Europea per lo Studio del Fegato (EASL).	CI

Altre lingue

Arbutus: Q1 Earnings Snapshot	14/05
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update	14/05
Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	14/05
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver Congress 2025	08/05
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025	07/05
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025	07/05
Arbutus Biopharma Corporation Presents Clinical Trial Data from Its Two HBV Assets, Imdusiran and AB-101, At the European Association for the Study of the Liver Congress 2025	07/05
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025	23/04
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025	23/04
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	27/03
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update	27/03
Arbutus Biopharma Corporation Announces CFO Changes, Effective from March 28 2025	27/03
Arbutus Biopharma Corporation to Reduce Workforce by 57% and Exits Warminster Headquarters	27/03
Arbutus Biopharma Corporation Announces Executive Changes	27/03
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement	03/03
Genevant Sciences And Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna	03/03
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna	03/03
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna	03/03
Roivant Sciences Announces Resignation and Replacement of Directors at Arbutus Biopharma	25/02
Arbutus Biopharma Names Lindsay Androski CEO, Overhauls Board	25/02
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO	25/02
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO	25/02
Arbutus Biopharma Corporation Announces Management Changes	25/02
Arbutus Biopharma Corporation Announces CEO Changes	25/02
Arbutus Biopharma : Corporate Presentation - January 2025	13/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Arbutus Biopharma Corporation

Azioni

ABUS

CA03879J1003

Biotecnologia

Altre lingue

Filtri